J&J COVID-19 vaccines at risk of going waste due to expiry in June

  • Hospitals, state health departments and the federal government have warned that millions of doses of Johnson & Johnson 's (NYSE:JNJ) COVID-19 vaccine could go to waste is not used as they near expiry this month, the New York Times reports.
  • Ohio has about 200,000 doses of the vaccine that Gov. Mike DeWine said were set to expire on June 23.
  • Arkansas' state epidemiologist said last week that as many as 60,000 doses of JNJ may not be used there in time.
  • Philadelphia has 42,000 J&J doses set to expire. West Virginia and Oklahoma are also among states that have thousands of J&J doses set to expire this month.
  • Pennsylvania's Department of Health said it worked with the Centers for Disease Control and Prevention (CDC) and Chester County to try to transfer its 50,000 expiring J&J doses to Oregon.
  • Over 10M doses of the vaccine have been delivered to states but not administered, according to CDC.
  • The federal government is encouraging governors to consult with the FDA on storage procedures as the agency examines how to possibly extend the shelf life of the vaccine.
  • 'We also continue to conduct stability testing with the goal of extending the amount of time our Covid-19 vaccine can be stored before expiry," the company said in a statement.
  • States and healthcare providers are also seeking federal guidance to redistribute the expiring doses and meanwhile improvise on incentives to entice people to get vaccinated.
  • Just over half of the 21.4M J&J shots distributed to providers have been administered, according to CDC, compared with 83% for shots from Moderna as well as Pfizer and its partner, BioNTech.
  • In early April, U.S. regulators paused the use of J&J's vaccine after reports of rare but severe blood clots. In response, vaccination sites canceled thousands of appointments and instead offered people Pfizer or Moderna doses instead of Johnson & Johnson 's single-dose shot.

    Over the current book year the total revenue from the company in New Brunswick will be 91.3 billion USD (consensus estimates). This is quite more than 2020's revenue of 82.58 billion USD.

    Historical revenues and results Johnson & Johnson plus estimates 2020

    historische koersen

    The analysts expect for 2021 a net profit of 25.49 billion USD. For this year most of the analysts expect a profit per share of 9.52 USD. Based on this the price/earnings-ratio is 17.28.

    Per share the analysts expect a dividend of 4.19 USD per share. The dividend yield is then 2.55 percent. The average dividend yield of the health care companies equals a low 1.46 percent.

    Most recent target prices around 177 USD

    Credit Suisse , ABN AMRO and KBC Securities recently provided recommendations for the stock.

    Based on the current number of shares Johnson & Johnson 's market capitalization equals 433.02 billion USD. The Johnson & Johnson stock was the past 12 months quite volatile. Since last June the stock is 17 percent higher. This year the stock price moved between 134 and 174 dollar.

    Historical stock prices Johnson & Johnson

    fundamental research johnson&johnson

    On Tuesday, the stock closed at 164.49 USD.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.